C. Clary

1.8k total citations
7 papers, 170 citations indexed

About

C. Clary is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, C. Clary has authored 7 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in C. Clary's work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Research Studies (3 papers) and Lung Cancer Diagnosis and Treatment (2 papers). C. Clary is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Research Studies (3 papers) and Lung Cancer Diagnosis and Treatment (2 papers). C. Clary collaborates with scholars based in France, Canada and India. C. Clary's co-authors include D. Spaëth, R. Gervais, Paul Rebattu, B. Milleron, Jean‐François Morère, É. Lemarié, David Braun, D. Debieuvre, A Depierre and Jean-Luc Breton and has published in prestigious journals such as Cancer, Annals of Oncology and Lung Cancer.

In The Last Decade

C. Clary

7 papers receiving 161 citations

Peers

C. Clary

PRM

ONCOL

CR

MB

EPIDE

Marie-Paule Lebitasy France

P. Bombaron France

Sae Wada Japan

Hirotaka Matsumoto Japan

Govind K Babu India

William Lawler United States

Michael Williamson Ireland

Aldo Renault France

Sara Manglaviti Italy

Carlotta Defferrari Italy

Marie-Paule Lebitasy France

C. Clary

242 ×1.6

PRM

174 ×1.3

ONCOL

27 ×1.7

CR

17 ×1.1

MB

45 ×3.5

EPIDE

Citations per year, relative to C. Clary C. Clary (= 1×) peers Marie-Paule Lebitasy

Countries citing papers authored by C. Clary

Since Specialization

Citations

This map shows the geographic impact of C. Clary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Clary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Clary more than expected).

Fields of papers citing papers by C. Clary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Clary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Clary. The network helps show where C. Clary may publish in the future.

Co-authorship network of co-authors of C. Clary

This figure shows the co-authorship network connecting the top 25 collaborators of C. Clary. A scholar is included among the top collaborators of C. Clary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Clary. C. Clary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Pujol, Jean-Louis, Jean-Luc Breton, R. Gervais, et al.. (2005). Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Annals of Oncology. 16(4). 602–610. 101 indexed citations

2.

Douillard, Jean‐Yves, R. Gervais, G Dabouis, et al.. (2004). Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Annals of Oncology. 16(1). 81–89. 31 indexed citations

3.

Douillard, Jean‐Yves, R. Gervais, H. Lacroix, et al.. (2000). Preliminary results of a randomized study on first and second line chemotherapy strategy in stage IV non-small cell lung cancer (NSCLC), assessing docetaxel (D) and cisplatin (C) until progressive disease (PD) then vinorelbine (V) versus V-C until PD then D. Lung Cancer. 29(1). 91–92. 2 indexed citations

4.

Orehek, J, B Blaive, C. Clary, et al.. (1988). Treatment of brain metastases of lung cancer with high doses of etoposide (VP16–213). Cooperative study from the groupe français pneumo-cancérologie. European Journal of Cancer and Clinical Oncology. 24(2). 131–135. 21 indexed citations

5.

Clary, C., et al.. (1985). [Intravascular bronchiolo-alveolar tumor. Study of a form with angiosarcomatous tendency].. PubMed. 5(2). 107–14. 1 indexed citations

6.

Clary, C., René P. Michel, Nai‐San Wang, & Robert E. Hanson. (1983). Metastatic carcinoma: The lung as the site for the clinically undiagnosed primary. Cancer. 51(2). 362–366. 7 indexed citations

7.

Blaive, B, et al.. (1982). Efficacite de la vaccination par extraits ribosomaux dans le traitement preventif des episodes infectieux des bronchopathies chroniques. Médecine et Maladies Infectieuses. 12(8). 475–479. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact